MedCity News

Is Radiology at a Structural Breaking Point? What Will Move It to a Better Future?

US Representative Scrutinizes Practices of IDR Entities

Rep. Frank Pallone, Jr., is seeking information from six IDR entities amid concerns about No Surprises Act arbitration practices and rising healthcare costs.

By Marissa Plescia

Survey Reveals AI Adoption is Accelerating in Healthcare, But Readiness is Not

The 2026 Healthcare AI Readiness Index, a new report by Cotiviti and MedCity News, is based on a survey of 70 healthcare leaders over the summer and shares candid views of how they balance harnessing AI with operational, regulatory and security challenges it creates. Download the report today!

By Stephanie Baum

Latest Video

Latest News

MedCity Influencers

Advancing Women’s Heart Health Through Prevention and Rapid Diagnosis

Early intervention based on accurate diagnosis of both metabolic risk factors and acute cardiac events could help make the difference between life and death for women.

By Lindy Carlstrom and Qian Ding

BioPharma, Pharma

GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs

GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers.

By Frank Vinluan

Health Tech

Oracle Health Execs Subpoenaed After VA Contract Costs Nearly Triple

The House VA Committee voted 19-0 to subpoena Oracle Health executives Larry Ellison and Mike Sicilia after learning the VA's EHR contract ballooned from $10 billion to $27 billion — despite Oracle's promise to Congress that it would absorb any costs beyond the original cap.

By Katie Adams

BioPharma, Pharma

FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease

Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the market without a commercialization partner.

By Frank Vinluan

MedCity Influencers

Bringing Ski Patrol Lessons to Healthtech Entrepreneurship

Three things ski patrol can teach about building a business

By Brian Van Winkle

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah

Health Tech

Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem

Judi Health expanded its healthcare network to offer specialized virtual care for cancer, autoimmune and GI conditions while helping employers reduce overall healthcare costs.

By Marissa Plescia

Hospitals, Providers

7 Hospital Mergers from Summer 2026

A roundup of the seven most notable hospital mergers and acquisitions announced or completed this summer, including Prisma Health’s acquisition of Erlanger Health and Sanford Health’s purchase of North Memorial Health

By Katie Adams

BioPharma, Pharma

Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder

Ultragenyx Pharmaceuticals’ apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The disappointing result has some readthrough to Ionis Pharmaceuticals and Oak Hill Bio, each in clinical development with Angelman drugs designed to work in a similar way as Ultragenyx’s failed molecule.

By Frank Vinluan

MedCity Influencers

Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands

This shift is not about replacing clinical care with tradition. It is about recognizing that healing in Native communities has always been deeply connected to culture.

By Selena Stockley

Devices & Diagnostics

3D computed tomography (CT) scan of the chest of a 60 year old male patient with a pneumothorax, or collapsed lung. The right lung (seen on the left) has collapsed due to a build-up of air between the lung and chest wall. Pneumothorax can be due to trauma or lung rupture. It causes shortness of breath and pain on breathing. It is treated by inserting a tube to drain the air over a period of days, allowing the lung to re-inflate

This Device Could Prevent Lung Biopsy’s Most Common — and Costly — Complication

Selio Medical developed an FDA-cleared hydrogel device that seals CT-guided lung biopsy punctures before they can cause pneumothorax — a collapsed lung complication that affects up to a third of the 800,000+ such biopsies performed annually in the U.S.

By Katie Adams

Health Tech

Thyme Care Raises $125M, Launches New Oncology Parent Entity

Thyme Care's Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health.

By Marissa Plescia

BioPharma, Pharma

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — eating food with gluten to see if it prompts an immune response. There are currently no FDA-approved drugs for celiac disease, but Teva’s antibody is part of a competitive race to bring patients the first one.

By Frank Vinluan

MedCity Influencers

Artificial intelligence in medicine. Doctor character uses ai app for patient diagnosis, medical analysis. Healthcare technology concept. Vector illustration.

The Healthcare Inflection Point: AI Can’t Fix 1990s Technology

Isolated improvements rarely translate into enterprise-wide transformation when they are layered onto outdated, inefficient workflows instead of being integrated into redesigned care delivery.

By Richard Atkin

Consumer / Employer, Policy

HHS Provides $77M in Grants for Substance Use Prevention, Mental Health

HHS awarded $77 million in SAMHSA grants for substance use prevention and treatment, mental health, suicide prevention and crisis services.

By Marissa Plescia